ML 2-14

ML 2-14 is a PROTAC targeting BRD4 with a C4 alkyl linker. ML 2-14 consists of the E3 ligase ligand EN219 (HY-115715) (bule part), the target protein ligand JQ-1 (HY-13030) (red part), and the PROTAC linker (balck part) . ML 2-14 can effectively degrade BRD4 in 231MFP breast cancer cells, and this effect can be reversed by the proteasome inhibitor Bortezomib (HY-10227) and the E1 activase inhibitor TAK-243 (HY-100487) [1].

Product Specifications

UNSPSC

12352005

Target

Epigenetic Reader Domain; PROTACs

Type

Reference compound

Related Pathways

Epigenetics; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ml-2-14.html

Purity

99.43

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

ClC1=CC=C(C=C1)C2=N[C@@H](CC(NCCCCOC3=CC=C(C4CC(C5=CC=C(Br)C=C5)=NN4C(CCl)=O)C=C3)=O)C6=NN=C(C)N6C7=C2C(C)=C(C)S7

Molecular Formula

C40H38BrCl2N7O3S

Molecular Weight

847.65

References & Citations

[1]Luo M, et al. Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function. Cell Chem Biol. 2021;28 (4) :559-566.e15.